# The Cooper Health System: Phase 1 study completed, 10 enrolled (Chronic Subdural Hematoma)

**Score:** 30/100

| Field | Value |
|---|---|
| Sponsor | The Cooper Health System |
| Sponsor type | Academic and hospital |
| Study | Chronic Subdural Hematoma Treatment With Intra-Arterial Bevacizumab Injection |
| NCT ID | NCT06510582 |
| Phase | Phase 1 |
| Status | completed |
| Conditions | Chronic Subdural Hematoma |
| Intervention types | drug |
| Target enrollment | 10 |
| Site countries | United States |
| Posted | 2024-07-19 |
| Planned start | 2024-06-17 |
| Event | Completed |
| Event date | 2026-09-28 |
| Last update posted | 2026-10-02 |

## Why this score
- Completed: closeout, analysis and the next study ahead.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06510582). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.